Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2008 2
2009 2
2010 5
2011 5
2012 4
2013 6
2014 4
2015 4
2016 4
2017 3
2018 7
2019 4
2020 4
2021 9
2022 8
2023 10
2024 9
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Arulanandam R, Bardoul A, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, O'Neill LA, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D. Kurmasheva N, et al. Among authors: diallo js. Nat Commun. 2024 May 15;15(1):4096. doi: 10.1038/s41467-024-48422-x. Nat Commun. 2024. PMID: 38750019 Free PMC article.
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.
Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS. Taha Z, et al. Among authors: diallo js. Nat Commun. 2024 Aug 23;15(1):7267. doi: 10.1038/s41467-024-51498-0. Nat Commun. 2024. PMID: 39179564 Free PMC article.
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.
Wedge ME, Jennings VA, Crupi MJF, Poutou J, Jamieson T, Pelin A, Pugliese G, de Souza CT, Petryk J, Laight BJ, Boileau M, Taha Z, Alluqmani N, McKay HE, Pikor L, Khan ST, Azad T, Rezaei R, Austin B, He X, Mansfield D, Rose E, Brown EEF, Crawford N, Alkayyal A, Surendran A, Singaravelu R, Roy DG, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller BA, Yamaguchi TN, Boutros PC, Geoffrion M, Rayner KJ, Chatterjee A, Auer RC, Diallo JS, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. Wedge ME, et al. Among authors: diallo js. Nat Commun. 2022 Apr 7;13(1):1898. doi: 10.1038/s41467-022-29526-8. Nat Commun. 2022. PMID: 35393414 Free PMC article.
Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Birdi HK, Jirovec A, Cortés-Kaplan S, Werier J, Nessim C, Diallo JS, Ardolino M. Birdi HK, et al. Among authors: diallo js. J Immunother Cancer. 2021 Feb;9(2):e001580. doi: 10.1136/jitc-2020-001580. J Immunother Cancer. 2021. PMID: 33526607 Free PMC article. Review.
Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi MJF, Diallo JS, Ilkow CS. Wong B, et al. Among authors: diallo js. Mol Ther. 2023 Nov 1;31(11):3127-3145. doi: 10.1016/j.ymthe.2023.09.012. Epub 2023 Sep 20. Mol Ther. 2023. PMID: 37735876 Free PMC article. Review.
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.
Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T. Rezaei R, et al. Among authors: diallo js. Nat Biomed Eng. 2024 Nov 28. doi: 10.1038/s41551-024-01259-7. Online ahead of print. Nat Biomed Eng. 2024. PMID: 39609558
Development and applications of oncolytic Maraba virus vaccines.
Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD. Pol JG, et al. Among authors: diallo js. Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Oncolytic Virother. 2018. PMID: 30538968 Free PMC article. Review.
SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
Gujar S, Bell J, Diallo JS. Gujar S, et al. Among authors: diallo js. Cell. 2019 Feb 21;176(5):1240-1240.e1. doi: 10.1016/j.cell.2019.01.051. Cell. 2019. PMID: 30794777 Free article.
92 results